Translating New Trials in IgAN
IgAN Content Hub
Heather N. Reich, MD, CM, PhD, FRCPC, Oreopoulos-Baxter Division Director of Nephrology, University of Toronto, discusses translating new clinical trials in IgA nephropathy, a kidney disease. Dr Reich highlights the growing interest in research and development of new treatments for the disease. Using a case study of a 24-year-old woman, she explains her approach to treatment decisions and interpreting clinical trials. Dr Reich also discusses the importance of risk stratification to provide patients with information about the risk of disease progression over time. Using an online international IgA nephropathy prediction tool, the speaker demonstrates how to estimate a patient’s risk of progression. The tool also allows for adjustments based on race, acknowledging that individuals of Pacific Asian descent may have a higher risk of progression.